Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of survival in patients with metastatic urothelial carcinoma: A multi-institutional study

International Journal of Urology

Volumn 22, Issue 7, 2015, Pages 638-643

  Taguchi, Satoru ^a   Nakagawa, Tohru ^a   Matsumoto, Akihiko ^b   Nagase, Yasushi ^b   Kawai, Taketo ^c   Tanaka, Yoshinori ^c   Yoshida, Kanae ^d   Yamamoto, Sachi ^d   Enomoto, Yutaka ^d   Nose, Yorito ^e   Sato, Toshikazu ^e   Ishikawa, Akira ^e   Uemura, Yukari ^f   Fujimura, Tetsuya ^a   Fukuhara, Hiroshi ^a   Kume, Haruki ^a   Homma, Yukio ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKYO METROPOLITAN TAMA MEDICAL CENTER   (Japan)

^c MUSASHINO RED CROSS HOSPITAL   (Japan)

^d MITSUI MEMORIAL HOSPITAL   (Japan)

^e TOKYO TEISHIN HOSPITAL   (Japan)

^f UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

Bladder cancer; Chemotherapy; Metastatic; Neutrophil to lymphocyte ratio; Urothelial carcinoma

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; C REACTIVE PROTEIN; CISPLATIN; CYTOTOXIC AGENT; HEMOGLOBIN; LACTATE DEHYDROGENASE;

ADULT; AGE; AGED; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BODY MASS; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; L CELL LINE; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; LIVER METASTASIS; LYMPH NODE METASTASIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METASTATIC UROTHELIAL CARCINOMA; NEUTROPHIL COUNT; NEUTROPHIL LYMPHOCYTE RATIO; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PROTEIN BLOOD LEVEL; SALVAGE THERAPY; SURVIVAL TIME; TRANSITIONAL CELL CARCINOMA; CARCINOMA, TRANSITIONAL CELL; CLINICAL TRIAL; CYTOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; NEUTROPHIL; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; UROLOGIC NEOPLASMS;

AGED; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; NEUTROPHILS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; UROLOGIC NEOPLASMS;

EID: 84937072850     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/iju.12766     Document Type: Article

References (29)

1. von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J. Clin. Oncol. 2000; 18: 3068-77.
2. von der Maase H, Sengelov L, Roberts JT et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol. 2005; 23: 4602-8.
3. Taguchi S, Nakagawa T, Hattori M et al. Prognostic factors for metastatic urothelial carcinoma undergoing cisplatin-based salvage chemotherapy. Jpn. J. Clin. Oncol. 2013; 43: 923-8.
4. Templeton AJ, McNamara MG, Šeruga B et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J. Natl. Cancer Inst. 2014; 106: dju124.
5. Tanaka N, Kikuchi E, Kanao K et al. A multi-institutional validation of the prognostic value of the neutrophil-to-lymphocyte ratio for upper tract urothelial carcinoma treated with radical nephroureterectomy. Ann. Surg. Oncol. 2014; 21: 4041-8.
6. Azuma T, Matayoshi Y, Odani K et al. Preoperative neutrophil-lymphocyte ratio as an independent prognostic marker for patients with upper urinary tract urothelial carcinoma. Clin. Genitourin. Cancer 2013; 11: 337-41.
7. Dalpiaz O, Ehrlich GC, Mannweiler S et al. Validation of pretreatment neutrophil-lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma. BJU Int. 2014; 114: 334-9.
8. Dalpiaz O, Pichler M, Mannweiler S et al. Validation of the pretreatment derived neutrophil-lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma. Br. J. Cancer 2014; 110: 2531-6.
9. Luo HL, Chen YT, Chuang YC et al. Subclassification of upper urinary tract urothelial carcinoma by the neutrophil-to-lymphocyte ratio (NLR) improves prediction of oncological outcome. BJU Int. 2014; 113: E144-9.
10. Viers BR, Boorjian SA, Frank I et al. Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy. Eur. Urol. 2014; 66: 1157-64.
11. Gondo T, Nakashima J, Ohno Y et al. Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy. Urology 2012; 79: 1085-91.
12. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat. Med. 1996; 15: 361-87.
13. Pencina MJ, D'Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat. Med. 2004; 23: 2109-23.
14. Matsuo S, Imai E, Hishida A et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am. J. Kidney Dis. 2009; 53: 982-92.
15. Takahashi S, Suzuki M, Kume H, et al. Combination chemotherapy of docetaxel, ifosfamide and cisplatin (DIP) in patients with metastatic urothelial cancer: a preliminary report. Jpn. J. Clin. Oncol. 2005; 35: 79-83.
16. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140: 883-99.
17. Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin. Cancer Res. 2009; 15: 425-30.
18. Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010; 6: 149-63.
19. Müller I, Munder M, Kropf P, Hänsch GM. Polymorphonuclear neutrophils and T lymphocytes: strange bedfellows or brothers in arms? Trends Immunol. 2009; 30: 522-30.
20. Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996; 77: 1303-10.
21. Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology 2007; 121: 1-14.
22. Fogar P, Sperti C, Basso D et al. Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome. Pancreas 2006; 32: 22-8.
23. Saroha S, Uzzo RG, Plimack ER et al. Lymphopenia is an independent predictor of inferior outcome in clear cell renal carcinoma. J. Urol. 2013; 189: 454-61.
24. Galsky MD, Moshier E, Krege S et al. Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy. Cancer 2013; 119: 3012-9.
25. Lin CC, Hsu CH, Huang CY et al. Prognostic factors for metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens. Urology 2007; 69: 479-84.
26. Apolo AB, Ostrovnaya I, Halabi S et al. Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. J. Natl. Cancer Inst. 2013; 105: 499-503.
27. Nakagawa T, Hara T, Kawahara T et al. Prognostic risk stratification of patients with urothelial carcinoma of the bladder with recurrence after radical cystectomy. J. Urol. 2013; 189: 1275-81.
28. Kinoshita T, Ito H, Miki C. Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer 1999; 85: 2526-31.
29. Okamoto M, Hattori K, Oyasu R. Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell lines in vitro. Int. J. Cancer 1997; 72: 149-54.